Related references
Note: Only part of the references are listed.Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Silvia Stacchiotti et al.
CANCER (2021)
Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex
Catherine L. Salussolia et al.
Annual Review of Genomics and Human Genetics (2019)
ABI-009 (nab-Sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors
Shihe Hou et al.
CANCER RESEARCH (2019)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials
Alessandro Comandone et al.
ONCOLOGIST (2017)
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap et al.
LANCET (2016)
Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2013)
Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates
Mark A. Dickson et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years
N. Penel et al.
ANNALS OF ONCOLOGY (2011)
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa
A. Italiano et al.
ANNALS OF ONCOLOGY (2010)
Perivascular epithelioid cell neoplasms: pathology and pathogenesis
Andrew L. Folpe et al.
HUMAN PATHOLOGY (2010)
Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
Andrew J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
Jingxiang Huang et al.
BIOCHEMICAL JOURNAL (2008)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
PEComas: the past, the present and the future
Guido Martignoni et al.
VIRCHOWS ARCHIV (2008)
Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms
Heidi Kenerson et al.
HUMAN PATHOLOGY (2007)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats
P Kremer et al.
ANTI-CANCER DRUGS (2002)
Share Paper
